Rare sugar d-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7

Journal of Bioscience and Bioengineering

Volumn 106, Issue 3, 2008, Pages 248-252

  Yamaguchi, Fuminori ^a   Kamitori, Kazuyo ^a   Sanada, Keiko ^a   Horii, Mariko ^a   Dong, Youyi ^a   Sui, Li ^a   Tokuda, Masaaki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; cell cycle; d allose; p27kip1; thioredoxin interacting protein (TXNIP)

Indexed keywords

CELL CULTURE; CELL DEATH; CELLS; CYTOLOGY; GENE EXPRESSION; GLUCOSE; GROWTH KINETICS; SUGAR (SUCROSE); SUGARS; TUMORS;

5-FLUOROURACIL; CELL CYCLE; D-ALLOSE; P27KIP1; THIOREDOXIN INTERACTING PROTEIN (TXNIP);

CELL GROWTH;

ALLOSE; CYCLIN A; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; FLUOROURACIL; GLUCOSE; PROTEIN P53; PSICOSE; THIOREDOXIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NICK END LABELING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUOROURACIL; GLUCOSE; HUMANS; LIVER NEOPLASMS;

EID: 53649105913     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1263/jbb.106.248     Document Type: Article

References (27)

1. Mazzanti R., Gramantieri L., and Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol. Aspects Med. 29 (2008) 130-143
2. Blum H.E. Treatment of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 19 (2005) 129-145
3. Hu J.K., Li C.M., Chen X.Z., Chen Z.X., Zhou Z.G., Zhang B., and Chen J.P. The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma: a systematic review of published randomized controlled trials. J. Chemother. 19 (2007) 359-375
4. Lee T.K., Lau T.C., and Ng I.O. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother. Pharmacol. 49 (2002) 78-86
5. Leung T.W., Patt Y.Z., Lau W.Y., Ho S.K., Yu S.C., Chan A.T., Mok T.S., Yeo W., Liew C.T., Leung N.W., Tang A.M., and Johnson P.J. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res. 5 (1999) 1676-1681
6. Urabe T., Kaneko S., Matsushita E., Unoura M., and Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 55 (1998) 39-47
7. Pinedo H.M., and Peters G.F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6 (1988) 1653-1664
8. Santi D.V., McHenry C.S., and Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13 (1974) 471-481
9. Izumori K. Bioproduction strategies for rare hexose sugars. Naturwissenschaften 89 (2002) 120-124
10. Sui L., Dong Y., Watanabe Y., Yamaguchi F., Hatano N., Izumori K., and Tokuda M. Growth inhibitory effect of d-allose on human ovarian carcinoma cells in vitro. Anticancer Res. 25 (2005) 2639-2644
11. Sui L., Dong Y., Watanabe Y., Yamaguchi F., Hatano N., Tsukamoto I., Izumori K., and Tokuda M. The inhibitory effect and possible mechanisms of d-allose on cancer cell proliferation. Int. J. Oncol. 27 (2005) 907-912
12. Yamaguchi F., Takata M., Kamitori K., Nonaka M., Dong Y., Sui L., and Tokuda M. Anticancer effects of rare sugar d-allose and molecular mechanisms of action in hepatocellular carcinoma cells. Int. J. Oncol. 32 (2008) 377-385
13. Takahashi Y., Nagata T., Ishii Y., Ikarashi M., Ishikawa K., and Asai S. Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol. Rep. 9 (2002) 75-79
14. El-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., and other 7 authors. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54 (1994) 1169-1174
15. Yoshikawa R., Kusunoki M., Yanagi H., Noda M., Furuyama J.I., Yamamura T., and Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 61 (2001) 1029-1037
16. Bloom J., and Cross F.R. Multiple levels of cyclin specificity in cell-cycle control. Nat. Rev. Mol. Cell Biol. 8 (2007) 149-160
17. Malumbres M., and Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 17 (2007) 60-65
18. Sheer C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
19. Tomoda K., Kubota Y., Arata Y., Mori S., Maeda M., Tanaka T., Yoshida M., Yoneda-Kato N., and Kato J.Y. The cytoplasmic shuttling and subsequent degradation of p27kip1 mediated by jab1/CSN5 and the COP9 signalosome complex. J. Biol. Chem. 277 (2002) 2302-2310
20. Tomoda K., Kubota Y., and Kato J. Degradation of the cyclin-dependent-kinas inhibitor p27kip1 is instigated by jab1. Nature 398 (1999) 160-165
21. Jeon J.H., Lee K.N., Hwang C.Y., Kwon K.S., You K.H., and Choi I. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res. 65 (2005) 4485-4489
22. Han S.H., Jeon J.H., Ju H.R., Jung U., Kim K.Y., Yoo H.S., Lee Y.H., Song K.S., Hwang H.M., Na Y.S., Yang Y., Lee K.N., and Choi I. VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 22 (2003) 4035-4046
23. Chen K., and DeLuca H.F. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim. Biophys. Acta 1219 (1994) 26-32
24. Chung J.W., Jeon J.H., Yoon S.R., and Choi I. Vitamin D3 up-regulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases. J. Dermatol. 33 (2006) 662-669
25. Ohta S., Lai E.W., Pang A.L., Brouwers F.M., Chan W.Y., Eisenhofer G., Krijger R., Ksinantova L., Breza J., Blazicek P., Kvetnansky R., Wesley R.A., and Pacak K. Down regulation of metastasis suppressor genes in malignant pheochromocytoma. Int. J. Cancer 114 (2005) 139-153
26. Ikarashi M., Takahashi Y., Ishii Y., Nagata T., Asai S., and Ishikawa K. Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease. Anticancer Res. 22 (2002) 4045-4048
27. Sheth S.S., Bodnar J.S., Ghazalpour A., Thipphavong C.K., Tsutsumi S., Tward A.D., Demant P., Kodama T., Aburatani H., and Lusis A.J. Hepatocellular carcinoma in Txnip-deficient mice. Oncogene 25 (2006) 3528-3536